Anabolic drugs activate osteoblasts and are an alternative to bisphosphonates for treating osteoporosis. Kristine Ensrud, MD, MPH, professor of medicine and epidemiology at the University of Minnesota and Minneapolis VA Healthcare System, joins JAMA Associate Editor Carolyn Crandall, MD, MS, to discuss the role of teriparatide, abaloparatide, and romosozumab in the management of osteoporosis.
Related Content: